Biotechnology News and Research

RSS

Companies, individuals and academic organizations recognized with GCOI awards

The Arizona Technology Council in partnership with the Arizona Department of Commerce today announced the winners of the 2009 Governor’s Celebration of Innovation (GCOI) awards.

20 Nov 2009

Elsevier journal Vaccine releases a supplement dedicated to vaccines for biodefense

Last week during the 'Vaccines for Biothreats and Emerging and Neglected Diseases Symposium' in Galveston TX, USA, the Elsevier journal Vaccine released a supplement dedicated to vaccines for biodefense (www.sciencedirect.com/science/journal/0264410X).

20 Nov 2009

TGen Drug Development and IPC collaborate to speed up research discoveries for cancer patients

TGen Drug Development (TD2) and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients.

20 Nov 2009

WPI researchers develop new model system to study fungal infections

A team of researchers at the Worcester Polytechnic Institute (WPI) Life Sciences and Bioengineering Center at Gateway Park has developed a new model system to study fungal infections. The system can be a powerful tool for screening potential drug targets for conditions like thrush, athlete's foot and vaginal yeast infections, which affect millions of people each year but are difficult to treat with existing medications. Using the new model, the researchers also identified a gene that may be a promising target for a new anti-fungal drug.

20 Nov 2009

CDAS, Prestwick Chemical sign drug discovery research agreement

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a strategic partnership between the company's contract research organization, Caliper Discovery Alliances & Services (CDAS), and Prestwick Chemical (Strasbourg, France) to provide customized outsourced medicinal chemistry and in vitro and in vivo preclinical biology programs for drug discovery research.

19 Nov 2009

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

19 Nov 2009

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

People with arthritis and leading Canadian and international researchers will share the stage under the theme "Decoding Arthritis - A Joint Effort" when the Canadian Arthritis Network (CAN) hosts its 2009 Annual Scientific Conference beginning tonight, in Vancouver, BC.

19 Nov 2009

Ligon Discovery raises $1 million

Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced that it has raised $1M in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets. With this investment, incTANK Ventures General Partner Christian Bailey joins the board.

19 Nov 2009

Advanced Cell Technology files an IND with the FDA for study using embryonic stem cells to treat SMD

Advanced Cell Technology, Inc. announced today that it filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Among the most common causes of untreatable blindness in the world are degenerative diseases of the retina.

19 Nov 2009

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.

19 Nov 2009

Vicor Technologies' PD2i nonlinear algorithm and software: a promising diagnostic for in-field trauma triage

David H. Fater, CEO of Vicor Technologies, Inc., today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), identified Vicor's proprietary PD2i® nonlinear algorithm and software as the most promising diagnostic for in-field trauma triage during a presentation before several hundred attendees at the American Heart Association's Resuscitation Science Symposium 2009 on November 14, 2009 in Orlando, Florida.

19 Nov 2009

ISCO, Scripps Research Institute collaborate in study of parthenogenetic stem cells

International Stem Cell Corporation, announced today that it is collaborating with renowned stem cell researcher Jeanne F. Loring, Ph.D., and the Scripps Research Institute (La Jolla, CA) to study parthenogenetic stem cells and potentially therapeutic cells that can be derived from them.

19 Nov 2009

ScinoPharm Taiwan receives the SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that ScinoPharm Taiwan Limited in Tainan, Taiwan has met the criteria established under the SafeBridge program for “Potent Compound Safety Certification” and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients (“APIs”).

19 Nov 2009

Washington Global Health Alliance completes internal coordination study of global health

The Washington Global Health Alliance, a group representing 26 life-sciences businesses, institutions and governmental organizations, has completed an internal coordination study demonstrating the significant influence of its primary partners in the mission of global health.

19 Nov 2009

RBM and Covance sign biomarker alliance and services agreement

Rules-Based Medicine, Inc. (RBM) today announced it has entered into a biomarker alliance and services agreement with Covance Inc. that will provide biotechnology and pharmaceutical companies with a powerful combination of biomarker technologies and services for use in drug development. Under terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM shall use Covance as its exclusive referral source for laboratory testing services.

19 Nov 2009

European Patent Office upholds Cellectis' EP 1 485 475 patent

Cellectis S.A., the French genome engineering specialist, has announced that the European Patent Office has today upheld European Patent EP 1 485 475 owned by Cellectis and relating to the invention of engineering methods for meganucleases. This method is based on the genetic fusion of meganuclease modules to obtain hybrid meganucleases.

19 Nov 2009

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

19 Nov 2009

Unique life science-focused application for social media site launched

Sigma-Aldrich® today announced the launch of a unique life science-focused application for the social media site, Facebook. Developed and marketed by Sigma® Life Science, the 'What's Your Favorite Gene?' application is the first and currently only application of its kind available on Facebook, and provides a platform that can enable scientists and researchers to network with each other and facilitate discussion based on their favorite genes, identifiable via gene functionality and biological pathways.

19 Nov 2009

Ecron Acunova establishes new office in Moscow, Russia

Ecron Acunova, a full-service clinical research organization (CRO), with offices across Europe, in India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow, Russia in October 2009.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Biotechnology News and Research

Companies, individuals and academic organizations recognized with GCOI awards

Elsevier journal Vaccine releases a supplement dedicated to vaccines for biodefense

TGen Drug Development and IPC collaborate to speed up research discoveries for cancer patients

WPI researchers develop new model system to study fungal infections

CDAS, Prestwick Chemical sign drug discovery research agreement

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Canadian Arthritis Network to host 2009 Annual Scientific Conference in Vancouver

Ligon Discovery raises $1 million

Advanced Cell Technology files an IND with the FDA for study using embryonic stem cells to treat SMD

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

Vicor Technologies' PD2i nonlinear algorithm and software: a promising diagnostic for in-field trauma triage

ISCO, Scripps Research Institute collaborate in study of parthenogenetic stem cells

ScinoPharm Taiwan receives the SafeBridge Potent Compound Safety Certification

Washington Global Health Alliance completes internal coordination study of global health

RBM and Covance sign biomarker alliance and services agreement

European Patent Office upholds Cellectis' EP 1 485 475 patent

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Unique life science-focused application for social media site launched

Ecron Acunova establishes new office in Moscow, Russia

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News